Article
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Mar 2013
Feller John K, Yang Shi, Mahalingam Meera
Abstract excerpt
The V600E mutation of BRAF has emerged as both an effective biomarker and therapeutic target for select benign and malignant cutaneous and non-cutaneous human tumors and is typically determined using DNA-based techniques that include allele-specific PCR and direct DNA sequencing. Recently however, the development of new antibodies directed against the V600E protein has opened the door for an easier and more...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
- Biomarkers, Tumor
- Cytoplasm
- DNA Mutational Analysis
- Female
- Genetic Predisposition to Disease
- Humans